Impax Labs (IPXL) to Resume Trading at 4:40pm ET
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St indexes fall to two-week lows as rising bond yields, disappointing Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Leerink Swann Downgrades Impax Laboratories (IPXL) to Market Perform
March 5, 2013 7:22 AM ESTLeerink Swann downgraded Impax Laboratories (NASDAQ: IPXL) from Outperform to Market Perform with a price target of $16.00 (from $23.00) after the FDA's follow-up inspection of IPXL's Hayward facility uncovered additional manufacturing deficiencies.
"Our prior thesis that IPXL would resolve its mfg.... More
Impax Labs (IPXL) Receives New Form 483 for Hayward Facility
March 4, 2013 4:15 PM ESTImpax Laboratories, Inc. (NASDAQ: IPXL) announced that the U.S. Food and Drug Administration (FDA) completed its re-inspection of the Companys Hayward manufacturing facility in connection with the previously disclosed Form 483 issued in March 2012. In addition to the re-inspection, the FDA conducted a Pre-Approval Inspection (PAI) for RYTARYTM, as analytical method validation and a portion of the stability data were generated in Hayward, and a general Good Manufacturing Practices (GMP) inspection. At the conclusion of this... More
Impax Labs (IPXL) trading halted with news pending
March 4, 2013 4:01 PM ESTImpax Labs, Inc. (NASDAQ: IPXL) trading halted with news pending.... More
